Enliven Therapeutics (ELVN) Shares Outstanding (Weighted Average) (2019 - 2026)

Enliven Therapeutics has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $62.8 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $62.8 million, up 25.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.8 million (up 25.47% YoY), and the FY2025 annual result was $56.7 million, up 20.38% from the prior year.
• Shares Outstanding (Weighted Average) came in at $62.8 million for Q1 2026 at Enliven Therapeutics, up from $56.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $62.8 million in Q1 2026 to a low of $2.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $42.1 million (2024), against an average of $37.1 million.
• Across the five-year window, Shares Outstanding (Weighted Average) plunged 85.58% in 2022 and surged 1323.85% in 2023, its largest moves.
• Enliven Therapeutics' Shares Outstanding (Weighted Average) stood at $3.1 million in 2022, then surged by 1037.74% to $35.5 million in 2023, then jumped by 32.43% to $47.1 million in 2024, then gained by 20.38% to $56.7 million in 2025, then advanced by 10.83% to $62.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $62.8 million (Q1 2026), $56.7 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.